2024-513372-18-00招募中2 期
Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally advanced or metastatic breast cancer previously treated with a CDK4/6 inhibitor in combination with hormonal therapy: a multicenter, phase II trial
Consorzio Oncotech, Consorzio Oncotech26 个研究点 分布在 1 个国家目标入组 168 人开始时间: 2024年5月29日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 168
- 试验地点
- 26
- 主要终点
- To evaluate the efficacy of the combination of fulvestrant plus palbociclib at the progression of a combined treatment of hormonal therapy (aromatase inhibitor or tamoxifen ± LHRHa) and CDK4/6 inhibitors with respect to: • Overall response rate (ORR) • Progression Free Survival (PFS) • 6-month PFS rate • Overall Survival (OS) • Safety and tolerability
研究概览
简要总结
The aim of the present study is to evaluate the efficacy and safety of palbociclib plus fulvestrant after failure of a combined treatment of hormonal therapy (aromatase inhibitor or tamoxifen ± LHRHa) plus a CDK4/6 inhibitor, in women with HR+ and HER2-LABC or MBC
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Adult (>=18 years of age) pre or post-menopausal women with LABC or MBC not amenable to curative treatment by surgery or radiotherapy, progressing to a CDK4/6 inhibitor in combination with aromatase inhibitor or tamoxifen in the adjuvant or metastatic setting. To be enrolled in the present trial patients must have relapsed at least after 12 months from the last CDK4/6 dosage in the adjuvant setting or at progression from a first line combined hormonal treatment for metastatic disease with a CDK4/6 inhibitor plus AI or Tam with duration of, at least, 6 months. For metastatic disease, patients must have achieved, at least a stable disease while the first line hormonal treatment with a CDK4/6 inhibitor plus AI or Tam to be enrolled in the trial.
- •Patients must perform liquid biopsy at study entry and at disease progression. Tissue biopsy of the most accessible metastatic site at study entry and at disease progression are required but not mandatory.
- •Written informed consent obtained before any screening procedure and according to local guidelines.
- •Patients receiving up to one line of chemotherapy before the first line hormonal treatment with a CDK4/6 inhibitor for metastatic disease may be enrolled in the study.
- •Histological confirmation of ER and/or PgR >= 1% and HER2 negative breast cancer (IHC status 0, 1+, 2+ and FISH not amplified).
- •Premenopausal women: in order to be eligible must have achieved surgical menopause with bilateral oophorectomy or ovarian radiation or medical menopause by treatment with a luteinizing hormone-releasing hormone (LHRH) agonist (LHRHa) for induction of ovarian suppression.
- •Radiological or objective evidence of recurrence or progression on or after the last systemic therapy prior to enrollment
- •Patients who received <= 28 days of fulvestrant for second line advanced breast cancer treatment prior to study enrollment are eligible.
- •Patients must have: - At least one lesion that can be accurately measured in at least one dimension >= 20 mm with conventional imaging techniques or >= 10 mm with spiral CT or MRI - Bone lesions: lytic or mixed (lytic + sclerotic) in the absence of measurable disease as defined above.
- •Adequate bone marrow and coagulation and adequate organ function defined as follows: - ANC > 1,000/mm3 (1.0 x 109/L); - Platelets > 75,000/mm3 (75 x 109/L); - Hemoglobin >= 9 g/dL (90 g/L); - Serum creatinine <= 1.5 x ULN or estimated creatinine clearance >= 60 ml/min as calculated using the method standard for the institution; - Total serum bilirubin <= 1.5 x ULN (<2.5 ULN if Gilbert’s disease); - AST and/or ALT <= 3 x ULN (<= 5 x ULN if liver metastases present); - Alkaline phosphatase <= 2.5 x ULN (<= 5 x ULN if bone or liver metastases present); - ECOG Performance Status <= 2; - Resolution of all acute toxic effects of prior therapy or surgical procedures to National Cancer Institute (NCI) CTCAE Grade <=1 (except alopecia).
- •Estimated life expectancy > of 12 weeks.
排除标准
- •HER2-overexpressing patients by local laboratory testing (IHC3+ staining or in situ hybridization positive).
- •Patients receiving concomitant immunosuppressive agents or chronic corticosteroids use, at the time of study entry except in cases outlined below: a. short duration (<2 weeks) of systemic corticosteroids is allowed (e.g., chronic obstructive pulmonary disease, anti-emetic); b. low doses of corticosteroids for brain metastasis treatment is allowed.
- •Patients with symptomatic visceral disease in need of urgent disease control (e.g., significant dyspnea related to pulmonary lymphangitic carcinomatosis and lung metastases or clinically meaningful symptomatic liver metastasis at the judgement of treating investigator).
- •Symptomatic brain metastases.
- •Patients with a known history of HIV seropositivity.
- •Active, bleeding diathesis, or on oral anti-vitamin K medication (except low dose warfarin, low-molecular-weight heparin (LMWH) and acetylsalicylic acid or equivalent, as long as the INR is <= 2.0).
- •Any severe and/or uncontrolled medical conditions such as: unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction <= 6 months prior to enrollment, serious uncontrolled cardiac arrhythmia.
- •Acute and chronic, active infectious disorders.
- •Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study treatments (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome).
- •Inability to swallow oral medications.
- •Significant symptomatic deterioration of lung function.
- •Patients who received > 1 line of chemotherapy as treatment for MBC.
- •Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A (Rifabutin, Rifampicin, Clarithromycin, Ketoconazole, Itroconazole, Voriconazole, Ritinavir, Telithromycin) within the last 5 days prior to enrollment.
- •History of non-compliance to medical regimens.
- •Patients refusing to perform liquid biopsy at study entry and disease progression.
- •Patients unwilling to or unable to comply with the protocol.
- •Patients who received > 1 line of a CDK4/6 inhibitor in combination with hormonal treatment for LABC or MBC or who have relapsed at less than 12 months from the end of adjuvant treatment with a CDK4/6 inhibitor. For metastatic disease, patients with a progressive disease within the first 6 months of treatment while on first line therapy with a CDK4/6 inhibitor, will be excluded.
- •Patients receiving chemotherapy or any type of hormonal therapy after treatment with a CDK4/6 inhibitor for metastatic disease.
- •Patients interrupting the previous treatment with CDK4/6 inhibitor for cardiac and/or hepatic toxicity and not for disease progression.
- •Pregnant, lactating women.
- •Known hypersensitivity to CDK4/6 inhibitors, fulvestrant, or to any of the excipients.
- •Radiotherapy within four weeks prior to enrollment (baseline/treatment start) except in case of localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture which can then be completed within two weeks prior to enrollment (baseline/treatment start). Patients must have recovered from radiotherapy toxicities prior to enrollment.
- •Currently receiving hormone replacement therapy, unless discontinued prior to enrollment.
结局指标
主要结局
To evaluate the efficacy of the combination of fulvestrant plus palbociclib at the progression of a combined treatment of hormonal therapy (aromatase inhibitor or tamoxifen ± LHRHa) and CDK4/6 inhibitors with respect to: • Overall response rate (ORR) • Progression Free Survival (PFS) • 6-month PFS rate • Overall Survival (OS) • Safety and tolerability
To evaluate the efficacy of the combination of fulvestrant plus palbociclib at the progression of a combined treatment of hormonal therapy (aromatase inhibitor or tamoxifen ± LHRHa) and CDK4/6 inhibitors with respect to: • Overall response rate (ORR) • Progression Free Survival (PFS) • 6-month PFS rate • Overall Survival (OS) • Safety and tolerability
次要结局
- To assess predictive biomarkers of response/resistance to fulvestrant plus palbociclib using metastatic tumor tissue samples and liquid biopsies.
研究者
Sabino De Placido
Scientific
Consorzio Oncotech
研究点 (26)
Loading locations...
相似试验
进行中（未招募）
1 期
Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally advanced or metastatic breast cancer previously treated with a CDK4/6 inhibitor in combination with hormonal therapy: a multicenter, phase II trialPre- and post-menopausal women with HR+/HER2- LABC or MBC whose disease has progressed to CDK4/6 inhibitor in combination with a hormonal therapy in the adjuvant or metastatic settingMedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104CTIS2024-513372-18-00Consorzio Oncotech168
进行中（未招募）
1 期
Palbociclib plus the drug fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally advanced or with metastases breast cancer previously treated with a CDK4/6 inhibitor in combination with hormonal therapy: a multicenter, phase II trialPre- and post-menopausal women with HR+/HER2- LABC or MBC whose disease has progressed to CDK4/6 inhibitor in combination with a hormonal therapy in the adjuvant or metastatic settingMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 100000004864EUCTR2019-000221-45-ITCONSORZIO ONCOTECH168
Unknown
2 期
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal TherapyMetastatic Breast CancerLocally Advanced Breast CancerNCT04318223Consorzio Oncotech168
招募中
4 期
Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer with focus on digital side effect management
The MINERVA Trial – A phase IV Trial2024-511209-49-00Universitaetsklinikum Ulm AöR285
尚未招募
3 期
Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast CancerBreast Cancer2024-513540-29-00Alliance Foundation Trials LLC303